Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05482321 · ClinicalTrials.gov registry record

Pancreas Ultrasound Imaging in type1 Diabetes

A clinical trial of Type 1 Diabetes and Pancreas Inflamed, sponsored by University of Colorado, Denver.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT05482321: Recruiting study of Type 1 Diabetes and Pancreas Inflamed, sponsored by University of Colorado, Denver.

NCT05482321 is a study of Type 1 Diabetes and Pancreas Inflamed that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 50 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05482321, a study of Type 1 Diabetes and Pancreas Inflamed, is actively recruiting participants, sponsored by University of Colorado, Denver.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this study is to develop and test a novel method involving ultrasound imaging, in order to detect the development of type 1 diabetes. In this study the investigators will first establish a standard operating procedure for measuring pancreas blood flow speed and volume in the pancreas of human subjects. The investigators will then determine 1) whether these pancreas blood flow factors differ between healthy subjects and those who have recently developed type1 diabetes; and 2) how variable measurements are in healthy subjects and subjects that recently developed type1 diabetes, both between subjects and over time. To address these aims the investigators will perform pancreas ultrasound measurements in each subject using an approved injectable 'bubble' contrast agent that allows measurement of pancreas blood flow. The investigators will compare ultrasound measurement with characteristics of the subject's type 1 diabetes, including genetic factors, glucose levels and other circulating factors, as well as other factors that may influence blood flow in the pancreas independent of type1 diabetes. The successful conclusion of this study will indicate whether measuring pancreas blood flow speed/volume will be helpful in monitoring whether type1 diabetes will emerge and thus will allow a large scale study to answer this question.

Primary Outcome

Optimized a contrast-enhanced ultrasound 'destruction-replenishment' protocol for imaging pancreas blood flow kinetics in adult human subjects.

Interventions

  • DRUG Definity Suspension for Injection

Study Locations (1)

Colorado

  • University of Colorado Anschutz, Barbara Davis Center - Aurora

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-02-27
Est. Completion 2025-09
University of Colorado, Denver

1,283 total trials

What NCT05482321 shows while recruiting

NCT05482321 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (93% lower).

The record links to 3 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Definity Suspension for Injection is the first listed.

NCT05482321 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT05482321 about?

NCT05482321 is a clinical study titled "Pancreas Ultrasound Imaging in type1 Diabetes". The overall goal of this study is to develop and test a novel method involving ultrasound imaging, in order to detect the development of type 1 diabetes. In this study the investigators will first establish a standard operating procedure for measuring pancreas blood flow speed and volume in the panc...

What is the current status of trial NCT05482321?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2023-02-27. Estimated completion is 2025-09.

What conditions does trial NCT05482321 study?

This clinical trial studies the following conditions: Type 1 Diabetes, Pancreas Inflamed, Insulitis.

What interventions are being tested in trial NCT05482321?

The interventions under investigation include: Definity Suspension for Injection (DRUG).

Who is sponsoring clinical trial NCT05482321?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05482321 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05482321's enrollment target sits among peer trials

50 87th of 198 higher than 107 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05482321, the US trial registry maintained by the National Library of Medicine. NCT05482321 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.